Mixed lineage leukemia (MLL) rearrangements occur in 80% of infants and 5% of older children with acute lymphoblastic leukemia (ALL). These cases have a poor prognosis with current therapy. The FLT3 kinase is overexpressed and constitutively activated in MLL-rearranged ALL cells. The FLT3 inhibitor CEP-701 selectively kills these cells, but is unlikely to be curative if used as monotherapy. To identify potentially synergistic combination strategies, we studied CEP-701 and six standard chemotherapeutic agents in three sequences of exposure (S1: chemotherapy followed by CEP-701, S2: simultaneous exposure to both; and S3: CEP-701 followed by chemotherapy) using MLL-rearranged ALL cell lines and patient bone marrow samples. MTT cytotoxicity and annexin V binding apoptosis assays were used to assess antileukemic effects. Combination indices (CI) were calculated for each combination (CIo0.9 -synergistic; CI 0.9-1.1 -additive; CI41.1 -antagonistic). A striking pattern of sequence-dependent synergy was observed: S1 was markedly synergistic (mean CI ¼ 0.5970.10), S2 was additive (mean CI ¼ 0.9970.09) and S3 was antagonistic (mean CI ¼ 1.2370.10). The sequence dependence is attributable to the effect of CEP-701 on cell cycle kinetics, and is mediated specifically by FLT3 inhibition, as these effects are not seen in control cells without activated FLT3.
Introduction
Although the cure rate for childhood acute lymphoblastic leukemia (ALL) overall now exceeds 80% the prognosis for certain molecularly defined high-risk subsets of childhood ALL remains poor. One of these high-risk subsets includes infants and older children whose leukemic cells harbor rearrangements of the mixed lineage leukemia (MLL) gene at chromosome 11q23, which includes 80% of infant and 5% of childhood ALL cases. The prognosis of these patients with standard therapy is dismal compared to age-matched ALL patients without MLL abnormalities. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] This is particularly true in the case of infants, where overall survival on most studies has been in the 20-30% range. 11, 12 Unlike some other high-risk subsets of childhood leukemia, neither intensification of standard chemotherapy regimens nor allogeneic hematopoietic stem cell transplantation has been successful in improving outcome for these patients. 8, 9 Novel therapies are clearly needed, and molecularly targeted agents represent a promising new therapeutic strategy.
The FLT3 tyrosine kinase has recently been implicated in the pathogenesis of MLL-rearranged ALL. Microarray studies have shown that FLT3 is the most consistently overexpressed gene in cases of MLL-rearranged ALL compared to other acute leukemias. [13] [14] [15] Activating mutations in the kinase domain of FLT3 have been reported to occur in up to 15% of infants and children MLL-rearranged ALL. [16] [17] [18] These data, the failure of standard therapy to cure the vast majority of these patients, and the clinical development of small molecules with FLT3 inhibitory activity have led to interest in FLT3 inhibition as a novel therapeutic approach for MLL-rearranged ALL. 16, [19] [20] [21] We have previously demonstrated that as a single agent in vitro, the FLT3 inhibitor CEP-701 selectively induces cytotoxicity and apoptosis in childhood ALL cells with high-level expression of constitutively activated FLT3, particularly those with MLL rearrangements. 20 Monotherapy with any single molecularly targeted agent, however, is unlikely to be curative in acute leukemia, which is thought to arise as the result of perturbations in multiple leukemogenic pathways. Targeted agents are more likely to be effective if rationally incorporated into multiagent combination chemotherapy treatment regimens. This study was undertaken in an effort to generate pre-clinical data that could be used to guide the incorporation of FLT3 inhibitors into existing chemotherapy regimens to improve the outcome for infants and children with MLL-rearranged ALL.
Materials and methods

Reagents
All cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA), except for fetal bovine serum (FBS), which was from Gemini (Woodland, CA, USA). CEP-701 was kindly provided by Cephalon Inc. (Frazer, PA, USA). All chemotherapeutic agents were obtained from Sigma (St Louis, MO, USA). CEP-701, daunomycin (DAUNO), etoposide (ETOP) and vincristine (VCR) were dissolved in dimethyl sulfoxide (DMSO) and stored at À801C. Dexamethasone (DEX) and cytarabine (ARA) were dissolved in water and stored at À801C. L-Asparaginase (LASP) was obtained as an aqueous solution and stored at 41C. All reagents were diluted into medium just before use. For every experiment described in this report, each sample, including the controls, contained an identical amount of DMSO. Phycoerythrin (PE)-conjugated annexin V, annexin V binding (AVB) buffer and 7-amino actinomycin D (7-AAD) were obtained from BD Biosciences (San Diego, CA, USA), anti-FLT3 S-18 antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and 4G10 anti-phosphotyrosine antibody and protein A agarose from Upstate Biotechnology (Lake Placid, NY, USA). Propidium iodide (PI) was obtained from Sigma.
Cell lines and primary patient samples
Cell lines were maintained in RPMI-1640 plus 10% FBS. Diagnostic bone marrow samples were collected under International Review Board-approved cell procurement protocols from newly diagnosed infants and children with ALL. Informed consent was obtained in accordance with the Helsinki protocol. Primary leukemic cells were enriched by Ficoll-Hypaque centrifugation, cultured in AIM V serum free-lymphocyte medium plus 10% FBS and assayed fresh. The diagnosis of ALL was based on morphology and flow cytometric analysis of immunophenotype. Cytogenetics was determined by standard procedures.
FLT3 immunoprecipitation and immunoblotting
Total and phosphorylated FLT3 protein expression was analyzed by incubating cells for 1 h in various concentrations of CEP-701 followed by cell lysis in detergent buffer, immunoprecipitation, gel electrophoresis and immunoblotting with antiphosphotyrosine antibodies as described previously.
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FLT3 genotyping
Total RNA was extracted from cells using RNeasy (Qiagen, Valencia, CA, USA). Two micrograms total RNA was reverse transcribed with random hexamer primers to generate cDNA, which was then used in PCR assays to amplify exons 14/15 (juxtamembrane domain or JMD, primers JMD-F, 5 0 -TGTCGAG CAGTACTCTAAACA and JMD-R, 5 0 -ATCCTAGTACCTTCC CAAACTC) and exon 20 (activation loop of kinase domain or KD, primers KD-F, 5
0 -GGCTGGAAGAAGAGGAGGAC and KD-R, 5 0 -GCCAGGGTAAGGATTCACAC). The polymerase chain reaction (PCR) products were used in FLT3 mutation screens we have developed for rapid detection of internal tandem duplications (exon 14/15, based on the appearance of a band with greater than expected size on 2.5% agarose gel) and D835/I836 point mutations (exon 20, based on loss of EcoRV restriction site). 22 All mutations were confirmed by direct sequencing of PCR products.
Cytotoxicity and apoptosis assays
Cytotoxicity assays were performed using 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium (MTT). Fifty microliters of culture medium with appropriate 2 Â concentration of drug(s) was aliquoted into triplicate wells of 96-well plates. Fifty microliters of cells suspended in culture medium was then added to each well. Plates were incubated at 371C, 5% CO 2 , and then the MTT assay was performed according to the manufacturer's instructions (Roche, Indianapolis, IN, USA). For AVB apoptosis assays, cells were incubated with drug(s) as above, then washed in phosphate-buffered saline (PBS) and resuspended in AVB buffer. Annexin V-PE and 7-AAD were added, and after incubation for 15 min, cells were sorted by flow cytometry (FACSCalibur, BD Biosciences) and analyzed with CellQuest software (BD Biosciences). The results of the MTT and AVB assays are expressed as a percent of untreated control. For the MTT assay, this is calculated as the mean OD of a triplicate of treated wells divided by the mean OD of a triplicate of control untreated wells, multiplied by 100%. For the AVB assay, this is calculated as the percent of viable cells in a treated sample (defined as cells that stain with neither annexin V nor 7-AAD) divided by the percent viable cells in an untreated control sample, multiplied by 100%.
Cell cycle analysis
Following drug exposure, cells were fixed in 70% cold methanol, washed in PBS with 0.5% bovine serum albumin and resuspended in PBS with 100 mg/ml RNAse (Roche). After incubation for 15 min at 371C, PI in PBS was added to a final concentration of 25 mg/ml and the cells were analyzed by flow cytometry.
Median effect analysis
The results of the MTT and AVB assays were analyzed by median effect analysis using Calcusyn software (Biosoft, Ferguson, MO, USA), which uses the principles developed by Chou and Talalay 23 to determine whether combinations of drugs are synergistic, additive or antagonistic. Briefly, dose-response curves are generated for each agent individually. Combination indices (CI) are then calculated for each combination of chemotherapy and CEP-701. Synergistic combinations are defined as those where the CI is less than 0.9, additive combinations give a CI between 0.9 and 1.1 and antagonistic combinations give a CI of greater than 1.1. We have described this analysis in more detail previously. 24 
Results
Response of cell lines to single agent CEP-701
We have previously analyzed seven childhood ALL cell lines for expression/activation of FLT3 protein and sensitivity to CEP-701. 20 We identified the HB-1119 and SEM-K2 cell lines, both of which are B-lineage childhood ALL cell lines that harbor MLL rearrangements, as those with the highest level expression of constitutively activated FLT3, and the greatest sensitivity to the cytotoxic effects of CEP-701. The HB-1119 and SEM-K2 cell lines therefore represent good models of MLL-rearranged ALL with high-level FLT3 expression and activation.
HB-1119 is a cell line derived from a child with ALL with a t(11;19) translocation (resulting in the MLL-ENL fusion protein). 25 We have discovered that this cell line also expresses an activating mutation in FLT3, namely a D835H substitution in the kinase domain (Figure 1a ), making it a good model of the combination of MLL rearrangement and FLT3 activating mutation, which has been shown to occur commonly in infant ALL. 17, 18 It expresses high levels of constitutively activated FLT3, and is potently killed by CEP-701 ( Figure 1a) .
SEM-K2 is a cell line derived from a child with ALL with a t(4;11) translocation (resulting in the MLL-AF4 fusion protein). 26 It expresses extremely high levels of constitutively activated wild-type FLT3 as a result of intrachromosomal amplification of the FLT3 gene. 16 It is also potently killed by CEP-701 ( Figure 1b ). RS4-11 is a cell line derived from an adult with ALL with a t(4;11)/MLL-AF4 fusion. 27 It expresses moderate levels of wildtype FLT3 that is minimally phosphorylated and is resistant to killing by CEP-701 ( Figure 1c ). RS4-11 was therefore used as a negative control in the following experiments.
CEP-701 causes dose-dependent G 1 cell cycle arrest in HB-1119 and SEM-K2, but not RS4-11 cells
We have previously reported that CEP-701 causes a G 1 cell cycle arrest in FLT3/ITD þ myeloid cell lines, and postulated that this property of CEP-701 may be responsible for the CEP-701 plus chemotherapy for MLL-rearranged ALL P Brown et al sequence specificity of the interactions between CEP-701 and chemotherapy. 24 To investigate the effects of FLT3 inhibition with CEP-701 on the cell cycle in MLL-rearranged ALL cell lines, we performed cell cycle analysis using PI staining and flow cytometric analysis on the cell lines after exposure to increasing doses of CEP-701 ( Figure 2 ). CEP-701 induces a dose-dependent G 1 cell cycle arrest in HB-1119 and SEM-K2, but not in RS4-11 cells.
Combinations of CEP-701 and chemotherapy result in a sequence-specific pattern of interaction in HB-1119 and SEM-K2, but not RS4-11 cells
We performed MTT cytotoxicity and AVB apoptosis assays of the cell lines exposed to CEP-701 plus six chemotherapy agents routinely used in the treatment of infants and children with ALL (VCR, DAUNO, ETOP, ARA, DEX and LASP). We tested these CEP-701 plus chemotherapy for MLL-rearranged ALL P Brown et al combinations in three sequences ( Figure 3) : (1) Detailed results of one combination (CEP-701 and VCR) for one cell line (SEM-K2) illustrate the nature of the primary data from which the summary figures below are derived. MTT results for the three sequences are shown in Figure 4a -c, comparing the cytotoxic effects of the chemotherapy only to the combination of chemotherapy plus CEP-701 (only the 20 nM dose is shown for simplicity). It can be seen that the combination results in increased cytotoxicity for sequence 1, but less cytotoxicity for sequence 3. AVB results for the same combinations are shown in Figure 4d , and reveal the same sequence-dependent pattern of synergy seen with the MTT assay, confirming that the enhanced cytotoxicity of the combination is primarily the result of increased induction of apoptosis. Median effect analysis for this combination reveals synergistic interaction for sequence 1, additive interaction for sequence 2 and antagonistic interaction for sequence 3 (Figure 4e and f) .
The summarized results of a similar analysis for all combinations with all three cell lines are shown in Figure 5 . Each of the 54 columns in Figure 5 represents the mean and s.d. of 8-12 combination data points. For both the HB-1119 and SEM-K2 cell lines, a specific, schedule-dependent pattern of synergy was observed (Figure 5a CEP-701 plus chemotherapy for MLL-rearranged ALL P Brown et al RS4-11 cell line, which is not dependent on FLT3 signaling, no significant interaction between CEP-701 and chemotherapy was observed, with all combinations demonstrating additivity regardless of the sequence of exposure (Figure 5c ). In summary, combinations of CEP-701 and chemotherapy agents consistently resulted in synergistic killing of the FLT3-dependent, MLLrearranged ALL cell lines when used in the specific sequence of exposure to chemotherapy followed by CEP-701. Less synergy is seen with simultaneous exposure, and exposure to CEP-701 followed by chemotherapy is generally antagonistic.
Antagonism of sequence 3 (CEP-701 followed by chemotherapy) results from the reversible cell cycle inhibiting effects of CEP-701
To test the hypothesis that the induction of cell cycle arrest by CEP-701 is the cause of the antagonistic interaction seen in sequence 3, we exposed SEM-K2 cells to CEP-701 and VCR according to the schematic shown in Figure 6a CEP-701 plus chemotherapy for MLL-rearranged ALL P Brown et al cytotoxicity assays demonstrated antagonism for the 'CEP-701' group (which was G 1 arrested at the start of the 48 h CEP-701/ VCR exposure), and additivity for the 'CEP-701-washout' group (which had been released from cell cycle arrest at the start of the 48 h CEP-701/VCR exposure) (Figure 6c ).
Response of primary infant and childhood leukemia cells to single agent CEP-701 and combinations of CEP-701 and chemotherapy
We sought to validate these findings by performing a similar series of experiments using primary patient samples. Figure 7 shows the response of three primary infant and childhood leukemia samples to CEP-701. All express high levels of constitutively phosphorylated wild-type FLT3, and demonstrate significant dose-dependent cytotoxicity with CEP-701 alone. Patient no. 1 is a child with wild-type MLL, whereas Patient nos. 2 and 3 are infants with MLL rearrangements (t(4;11)/MLL-AF4 fusion and t(11;19)/MLL-ENL fusion, respectively). The same cells were also treated with combinations of CEP-701 and chemotherapy using sequences 1 and 2 (we did not use sequence 3 owing to limited cell numbers and the low likelihood of using this sequence clinically, given the evidence of antagonism in the cell line studies). Similar patterns of sequence-specific synergy are seen, and there is again good correlation between MTT and AVB assays (Figure 8 ). Samples from Patient nos. 2 and 3 did not demonstrate a dose response to DEX, precluding median effect analysis for the CEP-701/DEX combination for these two samples. This is consistent with several published in vitro drug resistance studies demonstrating that samples from infants with MLL-rearranged ALL are relatively resistant to glucocorticoids. [28] [29] [30] The sample from Patient no. 3 also did not demonstrate a dose response to ARA. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] One can speculate, then, that the combination of chemotherapy followed by CEP-701 results in synergistic induction of apoptosis by inducing strong pro-apoptotic signals, then withdrawing important anti-apoptotic signals in actively cycling cells.
The cell line RS4-11, on the other hand, expresses low levels of minimally activated FLT3 and is relatively resistant to the cytotoxic effects of CEP-701. These cells demonstrate additivity with CEP-701 in combination with all agents regardless of sequence, and do not undergo cell cycle arrest on exposure to CEP-701. This suggests that the sequence-specific pattern of synergy seen in HB-1119 and SEM-K2 cells is, in fact, mediated largely through interactions between the FLT3 signaling pathway and the pathways affected by the various chemotherapeutic agents. We have validated these findings using three primary patient samples with high-level expression of constitutively activated FLT3, two of which are from infants with MLL gene rearrangements.
We have previously reported similar sequence dependency in our study of combinations of CEP-701 and chemotherapy in AML cells with FLT3 internal tandem duplications (FLT3/ITD). 24 We felt that it was important to examine the interactions of FLT3 inhibition with chemotherapy in MLL-rearranged ALL cells specifically, rather than making conclusions about these interactions based on those seen in studies of FLT3/ITD þ AML, as MLL-rearranged ALL is a fundamentally different disease than FLT3/ITD þ AML. One difference is that FLT3/ ITD is likely the primary leukemogenic 'hit' in FLT3/ITD þ AML, as (1) the vast majority of these cases have no other identifiable cytogenetic or molecular abnormality and (2) FLT3/ITD is transforming in many model systems. In MLL-rearranged ALL, the primary leukemogenic 'hit' is the MLL fusion protein, as demonstrated by many investigators in many model systems. FLT3 seems to play a secondary role in these leukemias. Another difference is that while FLT3 is markedly overexpressed and activated in MLL-rearranged ALL, in over 90% of these cases FLT3 activation is on the basis of overexpression of wild-type FLT3 with coexpression of FLT3 ligand. In only a minority of cases (3-15% in the published literature) is FLT3 activation on the basis of mutation, and nearly all of these are point mutations in the kinase domain of FLT3 (FLT3/PM) and not internal tandem duplications (FLT3/ITD), which are exceedingly rare in any form of ALL.
There are clear clinical differences between the two diseases as well. MLL-rearranged ALL occurs primarily in infants less than 1 year of age, whereas FLT3/ITD þ AML occurs primarily in adults. The phenotype of MLL-rearranged ALL is predominately lymphoid, with coexpression of myeloid markers in many cases, where FLT3/ITD þ AML has a myeloid phenotype. The spectrum of active cytotoxic agents for these two diseases is also very different. Glucocorticoids, VCR and LASP are key components of therapy for MLL-rearranged ALL, for example, where they are not generally useful for FLT3/ITD þ AML.
As the nature and role of FLT3 signaling and the clinical features are so different between these two diseases, one cannot assume a priori that the interaction between FLT3 inhibition and cytotoxic chemotherapy is the same in MLL-rearranged ALL as it is in FLT3/ITD þ AML. Our observation that there are significant similarities is, therefore, an important one that has clear clinical implications. Furthermore, we have shown that there are some real differences, particularly with regard to the interaction of simultaneous exposure, that also have clear clinical implications.
Perhaps, the major difference between the pattern of synergy seen in the current study and that seen in our study with FLT3/ ITD þ AML cells is the greater degree of synergy seen in the pretreatment sequence compared to the simultaneous exposure sequence for each chemotherapy/CEP-701 combination in the current study. In AML cells, we have noted similar degrees of synergy between these two sequences. The biologic basis of this observation is not clear, but may reflect a qualitative difference in the response to the combined effects of chemotherapy and FLT3 inhibition between cells with activated FLT3 on the basis of ITD mutations, and those with activated FLT3 through overexpression and autocrine stimulation of wild-type receptor or kinase domain mutations. This seems likely, as several studies have noted differences in various downstream signaling pathways between FLT3 receptor activated by ITD mutation and both wild-type FLT3 receptor activated by FLT3 ligand (FL) stimulation 22, [47] [48] [49] [50] and FLT3 receptor activated by kinase domain mutations. 51 Our data lead us to hypothesize that synergy between the antileukemic effects of standard cytotoxic chemotherapy and FLT3 inhibition will be optimized for patients with MLLrearranged ALL if FLT3 inhibitor therapy commences shortly after exposure to chemotherapy. As the chemotherapy regimens currently used for treating infants and children with ALL typically involve short bursts of intensive chemotherapy administration followed by a period of recovery, there is likely to be ample opportunity for the incorporation of FLT3 inhibitor therapy in a sequence that would test this hypothesis. A clinical trial is being designed based on these considerations. We are hopeful that the outcome for infants and children with MLLrearranged ALL will improve as a result of these efforts.
